TNF and inflammatory bowel disease: A propensity-matched cohort of IBD patients ≥ 50 years with CV comorbidities found no significant difference in MACE, including MI, between those receiving JAK inhibitors and TNF inhibitors over 12 months (adjusted OR 0.92; 95% CI 0.41–2.03) [78].